Research programme: intranasal chlamydia vaccine - NanoBio

Drug Profile

Research programme: intranasal chlamydia vaccine - NanoBio

Alternative Names: NE based chlamydia vaccine- NanoBio

Latest Information Update: 15 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoBio Corporation
  • Developer NanoBio Corporation; Queensland University of Technology
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Chlamydial infections

Most Recent Events

  • 02 Dec 2015 Preclinical trials in Chlamydial infections (Prevention) in Australia (Intranasal)
  • 02 Dec 2015 Pharmacodynamics and immunogenecity data from a preclinical trial in Chlamydial infections released by NanoBio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top